levomilnacipran

Known as: (1S,2R)-milnacipran 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2018
05101520122018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
The objective of this post-hoc analysis was to investigate the relationship between motivation/energy and functional impairment… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2015
2015
INTRODUCTION/OBJECTIVE Post hoc analyses were conducted to evaluate the efficacy of levomilnacipran extended-release (ER) in… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
2014
2014
Levomilnacipran (1S, 2R-milnacipran) is a potent and selective serotonin and norepinephrine reuptake inhibitor; an extended… (More)
  • table 1
  • figure 1
  • figure 2
  • table 3
  • table 4
Is this relevant?
2014
2014
BACKGROUND Major depressive disorder (MDD) is a global health concern. This study examined the efficacy, safety and tolerability… (More)
  • table 1
  • table 3
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2014
2014
Major depressive disorder (MDD) is characterized by increased rates of impaired function and disability. During antidepressant… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2014
2014
OBJECTIVE Levomilnacipran ER is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI) approved for the… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2013
2013
OBJECTIVE This phase 3, randomized, double-blind, placebo-controlled study evaluated the efficacy and tolerability of fixed-dose… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
2013
2013
Levomilnacipran (LVM; F2695) is the more active enantiomer of the serotonin/norepinephrine (5-HT/NE) reuptake inhibitor (SNRI… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2013
2013
OBJECTIVE To investigate the efficacy and safety of levomilnacipran sustained release (SR), an antidepressant candidate in late… (More)
Is this relevant?
2012
2012
A novel approach for the asymmetric synthesis of the active (1S,2R)-enantiomer of the antidepressant milnacipran is reported. The… (More)
Is this relevant?